5-methyl-7-(3-nitrophenyl)-8-acetyl-1,2,3,7-tetrahydroindolizine-6-carboxylic acid ethyl ester | 50620-89-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-methyl-7-(3-nitrophenyl)-8-acetyl-1,2,3,7-tetrahydroindolizine-6-carboxylic acid ethyl ester
• 英文别名: ethyl 8-acetyl-5-methyl-7-(3-nitrophenyl)-1,2,3,7-tetrahydroindolizine-6-carboxylate
• CAS: 50620-89-8
• 化学式: C₂₀H₂₂N₂O₅
• 分子量: 370.405
• InChiKey: SEGVHGGATAAWPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  92.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl (Z)-2-(3-nitrobenzylidene)-3-oxobutanoate 以 乙醇 为溶剂， 以72%的产率得到5-methyl-7-(3-nitrophenyl)-8-acetyl-1,2,3,7-tetrahydroindolizine-6-carboxylic acid ethyl ester
  参考文献：
  名称：

  Tetrahydroimidazolo[1,2-a]pyridine derivatives

  摘要：

  在3和5位带有羰基功能的1,4-二氢吡啶，可以在6位上选择性地被低碳基取代，在4位被低碳基，苯基，取代苯基或杂环基所取代，并通过1和2位与五，六或七元环烷基环融合，在其中一个亚甲基可以被硫，氧，亚胺或烷基亚胺取代，是抗高血压药和冠状血管扩张剂。这些化合物，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个代表性实施例，通过一个亚甲基乙酮酸酯和一个环状烯胺羰基衍生物的缩合制备。

  公开号：

  US03935220A1

文献信息

• 1,2-Pentamethylene-1,4-dihydropyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03951988A1

  公开（公告）日：1976-04-20

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，可在6位被低烷基取代，在4位被低烷基、苯基、取代苯基或杂环基取代，并通过1-和2-位与五、六或七元环烷基环融合，其中一个亚甲基可以被硫、氧、亚胺或烷基亚胺取代，是降压剂和冠状血管扩张剂。这些化合物，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个典型实施例，是通过酰乙酸酯和环烯酮羰基衍生物的缩合反应制备的。
• Pentahydroqunolizine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03948923A1

  公开（公告）日：1976-04-06

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropridine-3,5-dicar boxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，6-位可选择性地被低烷基取代，4-位被低烷基、苯基、取代苯基或杂环基取代，通过1-和2-位与五、六或七元环环烷基融合，其中一个亚甲基可以被硫、氧、亚胺或烷基亚胺取代，是降压剂和冠状血管扩张剂。这些化合物通过酰乙酸乙酯和环状烯氨酮羰基衍生物的缩合反应制备而成，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸二乙酯是一种代表性的实施例。
• Tetrahydroindolizine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03951994A1

  公开（公告）日：1976-04-20

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，可在6-位被低烷基取代，4-位被低烷基、苯基、取代苯基或杂环基取代，并通过1-和2-位融合到五、六或七元环环烷基环上，其中一个亚甲基可以被硫、氧、亚氨基或烷基亚氨基替换，是降压剂和冠状血管扩张剂。这些化合物的代表性实施例是6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯，通过酰乙酰乙酸酯和环状烯酰亚胺羰基衍生物的缩合制备。
• Bicyclic derivatives of 1,4-dihydropyridine as antihypertensive agents
  申请人：Bayer Aktiengesellschaft

  公开号：US04004015A1

  公开（公告）日：1977-01-18

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，可在6-位被低碳基取代，在4-位被低碳基、苯基、取代苯基或杂环基取代，并通过1-和2-位融合到五、六或七元环烷基环上，其中一个亚甲基可以被硫、氧、亚氨基或烷基亚氨基取代，是抗高血压药物和冠状血管扩张剂。这些化合物通过酰乙酰乙酸酯和环状烯酮羰基衍生物的缩合制备，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸二乙酯是一个典型的实施例。
• Compositions and methods employing tetrahydroindolizine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US04024261A1

  公开（公告）日：1977-05-17

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  在3-和5-位置带有羰基功能的1,4-二氢吡啶，可以在6-位置被低级烷基取代，4-位置被低级烷基、苯基、取代苯基或杂环基取代，并通过1-和2-位置与五、六或七元环烷基环融合，其中一种亚甲基基团可以被硫、氧、亚胺或烷基亚胺取代，是抗高血压药物和冠状血管扩张剂。这些化合物，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个具有代表性的实施例，可以通过酰乙酰乙酸酯和环状烯胺羰基衍生物的缩合制备。